Randomized Open-Label Phase 3 Trial Of Caspofungin Versus Fluconazole To Prevent Invasive Fungal Infections In Children Undergoing Chemotherapy For Acute Myeloid Leukemia (AML)
Brief description of study
If your child has been diagnosed with acute myeloid leukemia (AML) and is undergoing chemotherapy, you may qualify for a clinical trial comparing the effectiveness of two drugs, Caspofungin and Fluconazole in preventing invasive fungal infections. Purpose The goal of the study is to determine if administration of Caspofungin during periods of neutropenia (the presence of abnormally low white cells in the blood, leading to increased susceptibility to infection), following chemotherapy for AML is associated with a lower incidence of invasive fungal infections (IFI) and invasive Aspergillosis (IA) compared with fluconazole. The study will also determine if preventive treatment with Caspofungin will result in improved survival and less likelihood of receiving antifungal therapy compared to fluconazole.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.